Angiotech appoints Laura Brege to its Board of Directors
02 August 2007 - 2:00PM
PR Newswire (US)
VANCOUVER, Aug. 2 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company, today
announced that Laura Brege has been appointed to its Board of
Directors. Ms. Brege is currently Executive Vice President and
Chief Business Officer of Onyx Pharmaceuticals, Inc., where she
oversees Finance, including Information Technology; Business
Development; Legal; Human Resources, including Facilities;
Compliance and Investor Relations. Onyx Pharmaceuticals is focused
on developing and commercializing innovative cancer treatments.
"With her impressive background working as a CFO for two public
companies along with her in-depth knowledge of the healthcare
industry, we believe that Laura will be a strong addition to our
Board of Directors. As Angiotech continues to execute on our
commercialization strategy, we will benefit from Laura's expertise
in strategic finance, corporate development and operations," said
Dr. William Hunter, President and CEO of Angiotech. Prior to
joining Onyx Pharmaceuticals, Ms. Brege was a General Partner at
Red Rock Management, a venture capital firm specializing in early
stage financing for technology companies. Prior to her work at Red
Rock Management, she was the Senior Vice President and Chief
Financial Officer at COR Therapeutics, a biotechnology company that
specialized in drug therapies for cardiovascular disease. While at
COR, Ms. Brege was instrumental in helping the company grow from a
research and development start-up to an operations-based enterprise
with a commercialized product. Before joining COR, Ms. Brege was
Vice President and Chief Financial Officer at Flextronics, a
multi-billion dollar electronics manufacturer. She was also Vice
President and Treasurer of The Cooper Companies, a Fortune 500
diversified company with operations worldwide. Ms. Brege earned her
undergraduate degree from Ohio University and has an MBA from the
University of Chicago. Note on Forward Looking Statements
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing
the words "believes," "may," "plans," "will," "estimate,"
"continue," "anticipates," "intends," "expects" and similar
expressions, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements
are made pursuant to the "safe harbor" provisions of applicable
securities legislation. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially
different from any future results, events or developments expressed
or implied by such forward-looking statements. Many such risks,
uncertainties and other factors are taken into account as part of
our assumptions underlying these forward-looking statements and
include, among others, the following; general economic and business
conditions, both nationally and in the regions in which we operate;
market demand; technological changes that could impact our existing
products or our ability to develop and commercialize future
products; competition; existing governmental regulations and
changes in, or the failure to comply with, governmental
regulations; decisions, and the timing of decisions, made by health
regulatory agencies regarding approval of our technology and
products and decisions regarding reimbursement where applicable;
the requirement for substantial funding to conduct research and
development and to expand commercialization activities; and any
other factors that may affect performance. In addition, our
business is subject to certain operating risks that may cause the
actual results expressed or implied by the forward-looking
statements in this report to differ materially from our actual
results. These operating risks include; poor performance of the
product in the clinical setting; adverse events related to the use
of the product; improper estimation of the size of the product
markets; adverse results or unexpected delays in clinical
development processes; our ability to attract and retain qualified
personnel; our ability to successfully complete preclinical and
clinical development of our products; changes in business strategy
or development plans; our failure to obtain patent protection for
discoveries; loss of patent protection resulting from third party
challenges to our patents; commercialization limitations imposed by
patents owned or controlled by third parties; our ability to obtain
rights to technology from licensors; liability for patent claims
and other claims asserted against us; our ability to obtain and
enforce timely patent and other intellectual property protection
for our technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued
availability of capital to finance our activities; our ability to
continue to integrate into our business the operations of American
Medical Instruments Holdings, Inc. and our ability to achieve the
operational and other synergies and the other commercial or
financial benefits expected as a result of that acquisition; and
any other factors referenced in our annual information form and
other filings with the applicable Canadian securities regulatory
authorities or the SEC. Given these uncertainties, assumptions and
risk factors, readers are cautioned not to place undue reliance on
such forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.
About Angiotech Angiotech Pharmaceuticals, Inc. is a global
specialty pharmaceutical and medical device company with over 1,500
dedicated employees. Angiotech discovers, develops and markets
innovative treatment solutions for diseases or complications
associated with medical device implants, surgical interventions and
acute injury. To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. CONTACT: Jodi Regts, Manager, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (604) 221-7930, ; Analysts and Investors: Deirdre Neary,
Manager, Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., (604) 222-7056, DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Jodi Regts, Manager, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (604) 221-7930, ; Analysts and Investors: Deirdre Neary,
Manager, Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., (604) 222-7056,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024